Charles Buchen

Charles Buchen, MD has extensive work experience in the biopharmaceutical industry. Charles is currently serving as the Chief Business Officer at Cyprium Therapeutics, where they are responsible for leading the sell-side process for the successful asset sale of CUTX-101. Charles also played a key role in initiating the submission of a NDA to the FDA. Prior to this, they worked at Fortress Biotech as the Vice President of Business Development, where they evaluated investment opportunities and deals in various therapeutic areas. Charles also founded and operationalized new companies under the Fortress umbrella. Charles Buchen, MD has also held positions at Mustang Bio as the Head of Business Development, where they led the expansion of the company's pipeline of cell and gene therapies. Additionally, they founded Baergic Bio Inc, a biopharmaceutical company focused on developing treatments for CNS disorders, through a licensing and equity deal with AstraZeneca and Cincinnati Children's Hospital.

Charles Buchen, MD received a Doctor of Medicine (M.D.) degree from Albert Einstein College of Medicine. Prior to that, they obtained a Bachelor of Arts (B.A.) degree from Brooklyn College.